Point72 Asset Management L.P. Purchases New Stake in DBV Technologies SA – (DBVT)

Point72 Asset Management L.P. purchased a new stake in DBV Technologies SA – (NASDAQ:DBVT) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 51,600 shares of the company’s stock, valued at approximately $2,190,000. Point72 Asset Management L.P. owned about 0.10% of DBV Technologies at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Janus Henderson Group PLC raised its position in DBV Technologies by 10.1% during the 3rd quarter. Janus Henderson Group PLC now owns 2,797,789 shares of the company’s stock worth $118,738,000 after buying an additional 257,210 shares during the last quarter. Jennison Associates LLC raised its position in DBV Technologies by 86.4% during the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after buying an additional 464,341 shares during the last quarter. Citadel Advisors LLC purchased a new position in DBV Technologies during the 3rd quarter worth $7,794,000. Sectoral Asset Management Inc raised its position in DBV Technologies by 34.2% during the 2nd quarter. Sectoral Asset Management Inc now owns 179,152 shares of the company’s stock worth $6,398,000 after buying an additional 45,653 shares during the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of DBV Technologies by 9.1% in the 3rd quarter. Alps Advisors Inc. now owns 47,477 shares of the company’s stock valued at $2,015,000 after purchasing an additional 3,964 shares in the last quarter. Hedge funds and other institutional investors own 46.92% of the company’s stock.

A number of equities analysts have recently issued reports on DBVT shares. Deutsche Bank increased their price target on shares of DBV Technologies from $46.00 to $56.00 in a report on Sunday, October 8th. Zacks Investment Research upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Tuesday, October 24th. Morgan Stanley reissued an “overweight” rating and issued a $72.00 price objective (up from $70.00) on shares of DBV Technologies in a research note on Friday, October 6th. JMP Securities assumed coverage on shares of DBV Technologies in a research note on Friday, November 17th. They issued an “outperform” rating on the stock. Finally, Leerink Swann set a $49.00 price target on shares of DBV Technologies and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $49.63.

DBV Technologies SA – (NASDAQ DBVT) traded down $0.10 during midday trading on Friday, reaching $26.29. 88,880 shares of the company traded hands, compared to its average volume of 143,378. DBV Technologies SA – has a 52-week low of $20.58 and a 52-week high of $50.57.

ILLEGAL ACTIVITY NOTICE: “Point72 Asset Management L.P. Purchases New Stake in DBV Technologies SA – (DBVT)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/01/13/point72-asset-management-l-p-buys-new-position-in-dbv-technologies-sa-dbvt.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Institutional Ownership by Quarter for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply